Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective.
Journal: International journal of chronic obstructive pulmonary disease
Published: October 10, 2024
The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - The IMPACT trial.
Journal: Respiratory medicine
Published: October 13, 2023
Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK.
Journal: International journal of chronic obstructive pulmonary disease
Published: December 08, 2022
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
Journal: International journal of chronic obstructive pulmonary disease
Published: April 12, 2022
Getting control of hydrogel networks with cross-linkable monomers.
Journal: Journal of materials chemistry. B
Published: September 23, 2021
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Journal: International journal of chronic obstructive pulmonary disease
Published: July 29, 2021
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial.
Journal: ERJ open research
Published: May 14, 2021
Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
Journal: Journal of medical economics
Published: March 25, 2020
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Journal: International journal of chronic obstructive pulmonary disease
Published: May 17, 2019
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: December 12, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.
Journal: Respiratory medicine
Published: February 15, 2018
Last Updated: 09/26/2026